Do analysts recommend GOVX or PTIX?

GeoVax Labs currently has a consensus target price of $150.00, suggesting a potential upside of 20,791.36%. Given GeoVax Labs' stronger consensus rating and higher probable upside, equities analysts clearly believe GeoVax Labs is more favorable than Atrinsic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GOVX or PTIX more profitable?

Atrinsic's return on equity of 0.00% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -743.64% -394.74% Atrinsic N/A N/A -379.72%

Do analysts rate PTIX or GNPX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, PTIX or GNPX?

Atrinsic is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atrinsic N/A N/A -$5.53M -$3.45 N/A Genprex N/A N/A -$16.23M -$310.77 N/A

Is PTIX or GNPX more profitable?

Atrinsic's return on equity of 0.00% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets Atrinsic N/A N/A -379.72% Genprex N/A -247.32% -176.73%

Do analysts rate PTIX or DCOY?

Decoy Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 737.99%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Decoy Therapeutics is more favorable than Atrinsic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings & valuation, PTIX or DCOY?

Atrinsic is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atrinsic N/A N/A -$5.53M -$3.45 N/A Decoy Therapeutics N/A N/A -$12.52M -$106.90 N/A

Is PTIX or DCOY more profitable?

Atrinsic's return on equity of 0.00% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Atrinsic N/A N/A -379.72% Decoy Therapeutics N/A -315.22% -167.15%

Do analysts rate BDRX or PTIX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, BDRX or PTIX?

Atrinsic has lower revenue, but higher earnings than Biodexa Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodexa Pharmaceuticals $470K 3.33 -$8.42M N/A N/A Atrinsic N/A N/A -$5.53M -$3.45 N/A

Is BDRX or PTIX more profitable?

Company Net Margins Return on Equity Return on Assets Biodexa Pharmaceuticals N/A N/A N/A Atrinsic N/A N/A -379.72%

Do analysts prefer ABP or PTIX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, ABP or PTIX?

Abpro is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abpro N/A N/A -$7.23M -$4.23 N/A Atrinsic N/A N/A -$5.53M -$3.45 N/A

Is ABP or PTIX more profitable?

Company Net Margins Return on Equity Return on Assets Abpro N/A N/A -344.76% Atrinsic N/A N/A -379.72%

Atrinsic (PTIX) Competitors

$0.32 -0.04 (-10.94%)

As of 08/14/2026 11:23 AM Eastern

Compare

PTIX vs. GOVX, GNPX, DCOY, BDRX, and ABP

Should you buy Atrinsic stock or one of its competitors? Atrinsic's main competitors and comparable companies include GeoVax Labs (GOVX), Genprex (GNPX), Decoy Therapeutics (DCOY), Biodexa Pharmaceuticals (BDRX), and Abpro (ABP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Atrinsic compare to GeoVax Labs?

GeoVax Labs (NASDAQ:GOVX) and Atrinsic (NASDAQ:PTIX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Atrinsic's return on equity of 0.00% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-743.64%	-394.74%
Atrinsic	N/A	N/A	-379.72%

GeoVax Labs currently has a consensus target price of $150.00, suggesting a potential upside of 20,791.36%. Given GeoVax Labs' stronger consensus rating and higher probable upside, equities analysts clearly believe GeoVax Labs is more favorable than Atrinsic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, GeoVax Labs had 5 more articles in the media than Atrinsic. MarketBeat recorded 5 mentions for GeoVax Labs and 0 mentions for Atrinsic. GeoVax Labs' average media sentiment score of 0.57 beat Atrinsic's score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the media.

Company	Overall Sentiment
GeoVax Labs	Positive
Atrinsic	Neutral

GeoVax Labs has a beta of 3.73, meaning that its stock price is 273% more volatile than the broader market. Comparatively, Atrinsic has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market.

6.1% of GeoVax Labs shares are owned by institutional investors. Comparatively, 8.0% of Atrinsic shares are owned by institutional investors. 0.7% of GeoVax Labs shares are owned by company insiders. Comparatively, 8.0% of Atrinsic shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Atrinsic has lower revenue, but higher earnings than GeoVax Labs. Atrinsic is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	1.00	-$21.47M	-$11.34	N/A
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A

Summary

Atrinsic beats GeoVax Labs on 7 of the 13 factors compared between the two stocks.

How does Atrinsic compare to Genprex?

Atrinsic (NASDAQ:PTIX) and Genprex (NASDAQ:GNPX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

8.0% of Atrinsic shares are owned by institutional investors. Comparatively, 14.1% of Genprex shares are owned by institutional investors. 8.0% of Atrinsic shares are owned by insiders. Comparatively, 0.3% of Genprex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Atrinsic's return on equity of 0.00% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atrinsic	N/A	N/A	-379.72%
Genprex	N/A	-247.32%	-176.73%

In the previous week, Genprex had 3 more articles in the media than Atrinsic. MarketBeat recorded 3 mentions for Genprex and 0 mentions for Atrinsic. Genprex's average media sentiment score of 1.42 beat Atrinsic's score of 0.00 indicating that Genprex is being referred to more favorably in the news media.

Company	Overall Sentiment
Atrinsic	Neutral
Genprex	Positive

Atrinsic has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Genprex has a beta of -0.88, suggesting that its share price is 188% less volatile than the broader market.

Atrinsic is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A
Genprex	N/A	N/A	-$16.23M	-$310.77	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Atrinsic and Genprex tied by winning 5 of the 10 factors compared between the two stocks.

How does Atrinsic compare to Decoy Therapeutics?

Atrinsic (NASDAQ:PTIX) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

Decoy Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 737.99%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Decoy Therapeutics is more favorable than Atrinsic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

8.0% of Atrinsic shares are held by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are held by institutional investors. 8.0% of Atrinsic shares are held by insiders. Comparatively, 1.5% of Decoy Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Atrinsic has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market.

Atrinsic is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A

Atrinsic's return on equity of 0.00% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atrinsic	N/A	N/A	-379.72%
Decoy Therapeutics	N/A	-315.22%	-167.15%

In the previous week, Decoy Therapeutics had 2 more articles in the media than Atrinsic. MarketBeat recorded 2 mentions for Decoy Therapeutics and 0 mentions for Atrinsic. Decoy Therapeutics' average media sentiment score of 1.47 beat Atrinsic's score of 0.00 indicating that Decoy Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Atrinsic	Neutral
Decoy Therapeutics	Positive

Summary

Decoy Therapeutics beats Atrinsic on 8 of the 13 factors compared between the two stocks.

How does Atrinsic compare to Biodexa Pharmaceuticals?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and Atrinsic (NASDAQ:PTIX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biodexa Pharmaceuticals has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market. Comparatively, Atrinsic has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market.

Atrinsic has lower revenue, but higher earnings than Biodexa Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	$470K	3.33	-$8.42M	N/A	N/A
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
Atrinsic	N/A	N/A	-379.72%

In the previous week, Biodexa Pharmaceuticals had 2 more articles in the media than Atrinsic. MarketBeat recorded 2 mentions for Biodexa Pharmaceuticals and 0 mentions for Atrinsic. Biodexa Pharmaceuticals' average media sentiment score of 0.44 beat Atrinsic's score of 0.00 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Biodexa Pharmaceuticals	Neutral
Atrinsic	Neutral

17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. Comparatively, 8.0% of Atrinsic shares are held by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are held by insiders. Comparatively, 8.0% of Atrinsic shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Biodexa Pharmaceuticals beats Atrinsic on 6 of the 8 factors compared between the two stocks.

How does Atrinsic compare to Abpro?

Abpro (NASDAQ:ABP) and Atrinsic (NASDAQ:PTIX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

23.3% of Abpro shares are owned by institutional investors. Comparatively, 8.0% of Atrinsic shares are owned by institutional investors. 13.7% of Abpro shares are owned by insiders. Comparatively, 8.0% of Atrinsic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Abpro is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
Atrinsic	N/A	N/A	-379.72%

In the previous week, Abpro's average media sentiment score of 0.00 equaled Atrinsic'saverage media sentiment score.

Company	Overall Sentiment
Abpro	Neutral
Atrinsic	Neutral

Summary

Abpro beats Atrinsic on 4 of the 7 factors compared between the two stocks.

Get Atrinsic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTIX vs. The Competition

Export

Metric	Atrinsic	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$652K	$3.72B	$7.03B	$13.07B
Dividend Yield	N/A	3.69%	2.57%	10.65%
P/E Ratio	-0.04	10.77	271.26	25.38
Price / Sales	N/A	1,367.36	623.44	105.58
Price / Cash	N/A	101.42	75.70	53.27
Price / Book	0.16	16.78	12.92	6.21
Net Income	-$5.53M	-$13.32M	$3.45B	$347.71M
7 Day Performance	3.59%	1.76%	1.16%	1.08%
1 Month Performance	23.17%	2.86%	2.17%	1.87%
1 Year Performance	-89.06%	54.10%	62.38%	20.79%

Atrinsic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTIX Atrinsic	N/A	$0.32 -10.9%	N/A	-89.1%	$652K	N/A	N/A	2	Upcoming Earnings
GOVX GeoVax Labs	2.7729 of 5 stars	$0.72 -1.1%	$150.00 +20,797.2%	-96.2%	$2.52M	$2.49M	N/A	10	News Coverage Short Interest Decrease
GNPX Genprex	0.874 of 5 stars	$4.87 +3.0%	N/A	-98.1%	$2.39M	N/A	N/A	20	Positive News Earnings Report Short Interest Decrease
DCOY Decoy Therapeutics	2.1894 of 5 stars	$3.53 -1.9%	$30.00 +749.9%	N/A	$2.12M	N/A	N/A	20	Earnings Report Gap Down
BDRX Biodexa Pharmaceuticals	0.3457 of 5 stars	$1.56 +4.0%	N/A	-95.7%	$1.54M	$470K	N/A	20	Short Interest Increase Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTIX) was last updated on 8/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atrinsic (PTIX) Competitors

PTIX vs. GOVX, GNPX, DCOY, BDRX, and ABP

How does Atrinsic compare to GeoVax Labs?

Summary

How does Atrinsic compare to Genprex?

Summary

How does Atrinsic compare to Decoy Therapeutics?

Summary

How does Atrinsic compare to Biodexa Pharmaceuticals?

Summary

How does Atrinsic compare to Abpro?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTIX vs. The Competition

Atrinsic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atrinsic (PTIX) Competitors

PTIX vs. GOVX, GNPX, DCOY, BDRX, and ABP

How does Atrinsic compare to GeoVax Labs?

Is GOVX or PTIX more profitable?

Do analysts recommend GOVX or PTIX?

Does the media prefer GOVX or PTIX?

Which has more risk and volatility, GOVX or PTIX?

Do insiders & institutionals hold more shares of GOVX or PTIX?

Which has stronger valuation and earnings, GOVX or PTIX?

Summary

How does Atrinsic compare to Genprex?

Do institutionals & insiders hold more shares of PTIX or GNPX?

Is PTIX or GNPX more profitable?

Does the media favor PTIX or GNPX?

Which has more volatility and risk, PTIX or GNPX?

Which has preferable valuation and earnings, PTIX or GNPX?

Do analysts rate PTIX or GNPX?

Summary

How does Atrinsic compare to Decoy Therapeutics?

Do analysts rate PTIX or DCOY?

Do institutionals and insiders have more ownership in PTIX or DCOY?

Which has more volatility & risk, PTIX or DCOY?

Which has higher earnings & valuation, PTIX or DCOY?

Is PTIX or DCOY more profitable?

Does the media prefer PTIX or DCOY?

Summary

How does Atrinsic compare to Biodexa Pharmaceuticals?

Do analysts rate BDRX or PTIX?

Which has more risk and volatility, BDRX or PTIX?

Which has better earnings and valuation, BDRX or PTIX?

Is BDRX or PTIX more profitable?

Does the media refer more to BDRX or PTIX?

Do insiders and institutionals hold more shares of BDRX or PTIX?

Summary

How does Atrinsic compare to Abpro?

Do institutionals & insiders believe in ABP or PTIX?

Which has preferable valuation & earnings, ABP or PTIX?

Do analysts prefer ABP or PTIX?

Is ABP or PTIX more profitable?

Does the media favor ABP or PTIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTIX vs. The Competition

Atrinsic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools